Executive Summary New HCV Vaccine Research and Development
ثبت نشده
چکیده
NL Biotechnologies is a biotech R&D company that specializes in viral Hepatitis B, C, and E vaccine development. The proprietary recombinant Hepatitis B vaccine technology has been commercialized in 2002 by Instituto Butantan (Brazil) and in 2004 by Probiomed S.A. de C.V. (Mexico). The overall sales exceed 200 million doses. Since 2001, NL Biotechnologies in collaboration with CDC (US, Atlanta) has been developing novel vaccines against viral hepatitis. At present, we have several prospective candidates completed at lab-scale and ready for trials: hepatitis B prophylactic third generation vaccine (HBs-PreS1-PreS2), therapeutic hepatitis B fourth generation vaccine (HBs-HBc-PreS1-PreS2), two hepatitis C vaccine candidates and hepatitis E vaccine candidate. Currently, NL Biotechnologies is looking for partners in the industry for further clinical and commercial development.
منابع مشابه
Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus
Background: Hepatitis C virus (HCV) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. Therefore, designing new and effective therapeutics is of great importance. The aim of the current study was to construct a DNA vaccine containing structural proteins of HCV and evaluation of its expression in a eukaryot...
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملرویکردهای توسعه واکسن های پیشگیری کننده و درمانی علیه ویروس هپاتیت C
Introdution: An estimated 3% of the world population is chronically infected with hepatitis C virus (HCV), and it is a major health problem that causes cirrhosis and hepatocellular carcinoma. Despite the new directly acting antivirals (DAAs) for curing chronic hepatitis C virus (HCV) infection, the control of the disease has remained a global challenge. Several reasons, including presence of as...
متن کاملEvaluation of full length E1 and E2 glycoproteins of HCV expressed in P. pastoris as a protein-based vaccine candidate
Introduction: The development of an effective vaccine against Hepatitis C virus (HCV) is still a target of intensive vaccine research. The HCV envelope proteins E1 and E2 which can induce broadly neutralizing antibodies are the major candidate for this purpose. Different types of expression systems have been used to express these glycoproteins. In this study, an expression system using Pichia p...
متن کاملDevelopment of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein
Hepatitis C virus (HCV) is responsible for a vast majority of liver failure cases. HCV is a kind of blood disease appraised to chronically infect 3% of the worlds’ population causing significant morbidity and mortality. Therefore, a complete knowledge of humoral responses against HCV, resulting antibodies, and virus-receptor and virus-antibody interactions, are essential to design a vaccine. HC...
متن کامل